NITD008

NITD008

Clinical data
Trade names	NITD008
Identifiers
IUPAC name (2R,3R,4R,5R)-2-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
CAS Number	1044589-82-3 checkY
PubChem CID	44633776
ChemSpider	26376187
UNII	LKI7T3WQ2E
ChEMBL	ChEMBL1630221
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C13H14N4O4
Molar mass	290.279 g·mol−1
3D model (JSmol)	Interactive image
SMILES C#C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC3=C2N=CN=C3N)CO)O)O
InChI InChI=1S/C13H14N4O4/c1-2-13(20)9(19)8(5-18)21-12(13)17-4-3-7-10(14)15-6-16-11(7)17/h1,3-4,6,8-9,12,18-20H,5H2,(H2,14,15,16)/t8-,9-,12-,13-/m1/s1 Key:NKRAIOQPSBRMOV-NRMKKVEVSA-N

NITD008 is an antiviral drug classified as an adenosine analog (a type of nucleoside analog). It was developed as a potential treatment for flavivirus infections and shows broad spectrum antiviral activity against many related viruses such as dengue virus, West Nile virus, yellow fever virus, Powassan virus, hepatitis C virus, Kyasanur Forest disease virus, Omsk hemorrhagic fever virus, and Zika virus. However, NITD008 proved too toxic in pre-clinical animal testing to be suitable for human trials, but it continues to be used in research to find improved treatments for emerging viral diseases.

See also

• Favipiravir, a drug approved by China, Germany, Indonesia, Iran, Japan, Thailand, and Turkey for treating COVID-19 patients
• MK-608, a drug with a similar structure
• Remdesivir, FDA approved antiviral drug with a similar structure
• Ribavirin, another antiviral drug with teratogenic side effects that was patented by Merck in 1971 and approved by the FDA in 1986